Search results for "Molecular Pharmacology"

showing 6 items of 6 documents

Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way? [version 1; referees: 2 approved]

2016

Traumatic brain injury (TBI) is a leading cause of death and disability in the modern society. Although primary prevention is the only strategy that can counteract the primary brain damage, numerous preclinical studies have been accumulated in order to find therapeutic strategies against the secondary damage. In this scenario erythropoietin (EPO) has been shown to be a promising candidate as neuroprotective agent. A recent clinical trial, however, has shown that EPO has not an overall effect on outcomes following TBI thus renewing old concerns.  However, the results of a prespecified sensitivity analysis indicate that the effect of EPO on mortality remains still unclear. In the light of the…

Molecular PharmacologyNeuropharmacology & Psychopharmacologylcsh:Rlcsh:Medicinelcsh:Qlcsh:ScienceF1000Research
researchProduct

The pharmacology of the genus Sophora (Fabaceae): An updated review.

2019

Abstract Background The genus Sophora (Fabaceae) represents one of the important medicinal plant genera regarding its chemical constituents and outstanding pharmacological activities. Purpose In this review, we surveyed the latest findings on the bioactivities of different Sophora extracts and isolated phytochemicals during the past 8 years (2011–2019) updating the latest review article in 2011. The aim of this review is to focus on the molecular pharmacology of Sophora species to provide the rationale basis for the development of novel drugs. Results Sophora and its bioactive compounds possess outstanding pharmacological properties, especially as anticancer and anti-inflammatory drugs, in …

Conventional medicineAntifungalSophoramedicine.drug_classPhytochemicalsAnti-Inflammatory AgentsPharmaceutical SciencePharmacologyBiologyAntioxidants03 medical and health sciences0302 clinical medicineAnti-Infective AgentsGenusDrug DiscoverymedicineAnimalsHumans030304 developmental biologyPharmacology0303 health sciencesPlants MedicinalPlant ExtractsMolecular PharmacologyFabaceaebiology.organism_classificationAntineoplastic Agents PhytogenicComplementary and alternative medicineDrug development030220 oncology & carcinogenesisChemical constituentsEthnopharmacologyMolecular MedicineMedicine TraditionalSophoraPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Imaging of nitric oxide in a living vertebrate using a diaminofluorescein probe

2007

Abstract Numerous approaches have been described to identify nitric oxide (NO), a free radical involved in various physiological and pathophysiological processes. One of these approaches is based on the use of chemical probes whose transformation by NO generates highly fluorescent derivatives, permitting detection of NO down to nanomolar concentrations. Here, we show that the cell-permeant diaminofluorophore 4-amino-5-methylamino-2′-7′-difluorofluorescein diacetate (DAF-FM-DA) can be used to detect NO production sites in a living vertebrate, the zebrafish Danio rerio. The staining pattern obtained in larvae includes the bulbus arteriosus, forming bones, the notochord, and the caudal fin. Th…

Diagnostic Imagingmedicine.medical_specialtyDanioBulbus arteriosusNitric OxideBiochemistryNitric oxidechemistry.chemical_compoundPhysiology (medical)Internal medicineNotochordmedicineAnimalsZebrafishZebrafishFluorescent DyesbiologyfungiSnapMolecular Pharmacologybiology.organism_classificationStainingCell biologyEndocrinologymedicine.anatomical_structurechemistryLarvaFluoresceinFree Radical Biology and Medicine
researchProduct

Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way?

2016

Traumatic brain injury (TBI) is a leading cause of death and disability in the modern society. Although primary prevention is the only strategy that can counteract the primary brain damage, numerous preclinical studies have been accumulated in order to find therapeutic strategies against the secondary damage. In this scenario erythropoietin (EPO) has been shown to be a promising candidate as neuroprotective agent. A recent clinical trial, however, has shown that EPO has not an overall effect on outcomes following TBI thus renewing old concerns.  However, the results of a prespecified sensitivity analysis indicate that the effect of EPO on mortality remains still unclear. In the light of the…

0301 basic medicinemedicine.medical_specialtyMolecular PharmacologyNeuropharmacology & PsychopharmacologyTraumatic brain injurySolid baseBrain damageNeuroprotectionGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesTraumatic brain injury0302 clinical medicinePrimary preventionmedicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicineErythropoietin; Neuroprotection; Traumatic brain injuryErythropoietinCause of deathGeneral Immunology and Microbiologybusiness.industryArticlesGeneral MedicineOpinion Articlemedicine.diseaseNeuroprotectionClinical trial030104 developmental biologyErythropoietinmedicine.symptombusinessNeuroscience030217 neurology & neurosurgerymedicine.drugF1000Research
researchProduct

Overview of key molecular and pharmacological targets for diabetes and associated diseases

2021

Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by c…

0301 basic medicineDrugmedia_common.quotation_subjectDiseaseType 2 diabetesBioinformatics030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyNephropathyDiabetes Complications03 medical and health sciences0302 clinical medicineDiabetes mellitusDrug DiscoveryDiabetes MellitusAnimalsHumansHypoglycemic AgentsMedicineMolecular Targeted TherapyPharmacology & PharmacyGeneral Pharmacology Toxicology and Pharmaceuticsmedia_commonGlycemicbusiness.industry0601 Biochemistry and Cell Biology 1115 Pharmacology and Pharmaceutical SciencesGeneral MedicineMolecular PharmacologyA300medicine.diseaseHuman genetics030104 developmental biologybusinessSignal Transduction
researchProduct

Chemical-Biology of Natural Products from Medicinal Plants for Cancer Therapy

2010

Secondary metabolites are produced by an organism for defense towards competitors, herbivores, and pathogens. They also act as signal compounds to attract animals for pollination and seed dispersal. Fortunately, many secondary metabolites from plants exhibit diverse pharmacological features. Exploitation of these beneficial effects is the primary goal of researchers working in the area of molecular pharmacology of natural products. Natural products are among the major players in pharmacology in general and in cancer therapy in particular. A considerable portion of antitumor agents currently used in the clinic are of natural origin (e.g. Vinca alkaloids, taxanes, podophyllotoxin, camptotheci…

Natural productmedicine.drug_classChemical biologyComputational biologyMolecular PharmacologySecondary metaboliteBiologyVinca alkaloidchemistry.chemical_compoundchemistrymedicineNatural Product ResearchCamptothecinOrganismmedicine.drug
researchProduct